The rising number of children with major risk factors for cardiometabolic conditions represents a potential tsunami of preventable disease for our healthcare system.
A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods.
Cedars-Sinai investigators are developing a novel way to treat amyotrophic lateral sclerosis (ALS) and retinitis pigmentosa using engineered stem cells